After Terminating its Cooperation with Chinese Companies, Canada Now Said : It does not Rule Out that it will still Buy Chinese Vaccines

Canada announced last month that the Chinese company had terminated the new coronavirus vaccine cooperation, and then turned around and reached a purchase agreement with four US companies. Regarding a series of recent actions in Canada, the outside world has speculated whether the country 'abandoned China's investment in the United States' and abandoned the purchase of Chinese vaccines.

Regarding the above speculation, Canadian officials responded vaguely. On September 14, local time, Canadian Minister of Public Service and Government Procurement, Anita Anand, responsible for purchasing the new coronavirus vaccine, said that Canada does not rule out the possibility of purchasing vaccines from China and Chinese companies.

According to the public information of the World Health Organization, as of September 9, a total of 35 new coronavirus vaccines worldwide have entered the trial phase, of which a total of 9 have entered clinical phase III trials (large-scale volunteer trials), while China has exclusive 5 types.


At the press conference held on the morning of the 14th, a reporter asked whether the Canadian government will continue to seek to purchase the new coronavirus vaccine from China.

Anand replied, 'We are currently negotiating with many companies, but mainly based on the recommendations of the vaccine working group.' The Canadian new coronavirus vaccine working group is composed of 18 experts, including representatives from top research institutions and the largest pharmaceutical companies.

She added, 'I will not decide who to negotiate with or not. They (the working group) are working hard, and I will follow their advice and the Ministry of Health.'

The Canadian Politics Newspaper (iPolitics) pointed out that Anand’s words showed that after terminating cooperation with a Chinese company, Canada did not rule out the possibility of purchasing vaccines from China and Chinese companies, leaving room for negotiation.

On August 26, the National Research Council of Canada (NRC) stated that it had terminated its cooperation with the Chinese company CanSino Biologics Inc. in the development of new coronavirus vaccines, and claimed that it was because 'China Customs did not approve CanSino’s delivery of drugs testing in Canada'.

Reuters reported at the time that Canada 'will switch to looking for other partners' after terminating cooperation. Facts now prove that the so-called 'other partners' are American companies.

According to the Canadian Political Electronics News, as of now, Canada has reached an agreement with four U.S. companies to purchase tens of thousands of doses of the new coronavirus vaccine that they are still in the trial stage : in addition to the U.S. Pfizer and Moderna Biotech in early August, Prime Minister Trudeau announced two weeks ago that Canada has reached a partnership with Novavax and Johnson & Johnson.

Anand previously stated in an interview with the U.S. 'New York Times' that purchasing vaccines from multiple manufacturers and continuing to negotiate with other vaccine manufacturers is part of the government’s strategy of 'not putting eggs in one basket' because it has not yet known whose vaccine is effective.

'Because we don't know which vaccine will be successful, we must bet on multiple vaccines at the same time.' She also mentioned that although the government is ready to purchase more than 100 million doses of vaccines, it also pays attention to vaccines developed and manufactured in the country. .

It is worth noting that according to the public information of the World Health Organization, as of September 9, a total of 35 new coronavirus vaccines worldwide have entered the trial phase, of which a total of 9 have entered clinical phase III trials (large-scale volunteer trials), and China exclusively 5 kinds.